Rhythm Pharmaceuticals, Inc.'s SEC filings document a commercial-stage biopharmaceutical company whose disclosures center on IMCIVREE (setmelanotide), MC4R pathway rare-disease indications and related clinical and regulatory milestones. Recent Form 8-K reports include operating results, product-revenue commentary, FDA and European regulatory updates for acquired hypothalamic obesity, and trial disclosures for programs such as TRANSCEND and EMANATE.
Rhythm's proxy materials and governance filings disclose board composition, director elections, executive compensation, equity awards and shareholder voting matters. Other current reports record director changes, Regulation FD materials, presentations and press releases, tying corporate governance and public-company reporting to the company's rare neuroendocrine disease portfolio.
For Rhythm Pharmaceuticals, Inc. (RYTM), President and CEO David P. Meeker reported exercising options for 50,000 shares of common stock at an exercise price of $6.05 per share on September 14, 2026, and selling 50,000 shares in multiple transactions on the same day. The option exercise relates to awards granted in February 2017, and the exercise and sales were carried out under a Rule 10b5-1 trading plan adopted on June 15, 2026.
RHYTHM PHARMACEUTICALS, INC. (RYTM) is the issuer for which David Meeker has filed a notice of proposed sale of restricted or control securities under Rule 144. The notice covers a proposed sale of 50,000 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $5,235,500 as of the filing. The filing lists 68,852,082 shares of common stock outstanding and indicates the shares are to be sold on NASDAQ on or after September 14, 2026, following acquisition via exercise of stock options for cash.
RHYTHM PHARMACEUTICALS, INC. (RYTM) Chief Financial Officer Hunter C. Smith exercised 57,187 employee stock options on August 31, 2026 at an exercise price of $25.79 per share, receiving the same number of common shares. On the same date, he sold 62,774 common shares in multiple transactions at weighted average prices around $104.59, $105.37, and $106.20 per share, with each tranche executed in price ranges disclosed in the footnotes. The option exercised was granted on February 14, 2018 and vesting occurred in sixteen equal quarterly installments; 3,813 option shares remain outstanding, expiring February 13, 2028. All exercises and sales were made pursuant to a Rule 10b5-1 trading plan adopted on May 13, 2026.
RHYTHM PHARMACEUTICALS, INC. (RYTM) has a notice of proposed sales under Rule 144 filed for officer Hunter Smith. The notice covers potential sales of common stock related to an exercise of stock options for 57,187 shares dated August 31, 2026, and restricted stock units for 5,587 shares dated February 1, 2026. Morgan Stanley Smith Barney LLC Executive Financial Services is listed as the broker. The filing gives advance notice of possible sales but does not itself complete any transaction.
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported that Chief Medical Officer Manher Joshi received equity awards. He was granted 50,000 stock options with an exercise price of $115.44 per share, expiring August 16, 2036. These options vest 25% after one year, then 6.25% every three months of continued service.
He also received 25,000 Restricted Stock Units, vesting 25% on September 1 of each of 2027, 2028, 2029, and 2030, becoming fully vested on September 1, 2030, subject to continued service. Following these grants, he holds 50,000 options and 25,000 RSUs directly.
Rhythm Pharmaceuticals, Inc. (RYTM) reports an initial statement of beneficial ownership on Form 3 for Joshi Manher, who serves as Chief Medical Officer. The filing lists no equity transactions or holdings and notes an attached Exhibit 24 for a Power of Attorney, authorizing filings to be made on the officer’s behalf.
RHYTHM PHARMACEUTICALS, INC. executive Joseph Shulman, Chief Technical Officer, exercised 2,024 stock options at an exercise price of $6.80 per share into common stock on 2026-08-13 and sold 5,079 common shares at $119.75 per share. The options, granted on 2022-02-09 and vesting in 16 installments, now show 5,945 options reported as remaining. These transactions were effected under a Rule 10b5-1 trading plan adopted on 2025-12-15.
RHYTHM PHARMACEUTICALS, INC. executive Alastair Garfield, Chief Scientific Officer, reported selling a total of 7,763 shares of common stock on August 13, 2026 in four open‑market or private transactions. The sales, made under a Rule 10b5-1 trading plan adopted on May 14, 2026, occurred at weighted average prices of $116.1093, $117.0759, $118.2843, and $119.1688 per share, each representing multiple trades within stated price ranges.
Rhythm Pharmaceuticals EVP Jennifer Kayden Lee reported multiple transactions in company equity on August 13, 2026. She exercised stock options covering 56,601 shares of common stock at exercise prices of $24.29 and $6.80 per share, receiving the corresponding common shares. She then sold 75,834 shares of common stock at a price of $117.3818 per share. All exercises and sales were effected pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2026.
Rhythm Pharmaceuticals EVP Yann Mazabraud exercised stock options to acquire 46,625 shares of common stock at an exercise price of $6.80 per share and reported continuing to hold 35,875 stock options after the exercise. On the same date, he sold an aggregate of 57,000 shares of common stock in multiple open-market transactions at weighted-average prices ranging from approximately $111.58 to $117.60 per share. The exercise and sales were effected pursuant to a Rule 10b5-1 trading plan adopted on May 13, 2026, and the options exercised were part of a grant made on February 9, 2022 that vests in substantially equal quarterly installments.